As a treatment for postmenopausal osteoporosis, teriparatide increases bone mineral density (BMD) at several skeletal sites and is better than alendronate at preventing nonvertebral fractures, according to a recent report. In contrast to alendronate, a bisphosphonate that reduces bone resorption, teriparatide is a recombinant form of parathyroid hormone that stimulates bone formation.
Teriparatide, which is produced by Indianapolis-based Eli Lilly and Co. under the trade name Forteo, received preliminary approval by the US Food and Drug Administration last year as a treatment for osteoporosis (see Reuters Health story October 3, 2001).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!